The Numbers
In the studies the FDA reviewed before approving Wegovy, about 1 in 33 people on the peptide had extra hair shedding. In the placebo group, the rate was about 1 in 100.
So the peptide does add some hair shedding. A real difference, but a small one. The same pattern showed up in the tirzepatide research behind Mounjaro and Zepbound.
The Cause
The hair loss isn't caused by the peptide acting on hair. It's caused by the fast weight loss the peptide produces. The same shedding pattern shows up in any rapid weight loss: bariatric surgery, very-low-calorie diets, illness.
Dermatologists have a name for it: telogen effluvium, the synchronized shedding phase the body shifts into about two to four months after a metabolic shock. The hair grows back once weight stabilizes, usually over the next several months.
What this means
References3 sources
How to read these sources
This article uses primary sources and reviews to separate mechanism, human evidence, and context.
- Review
Obesity (Silver Spring)
Wiley / The Obesity SocietyNutritional priorities to support GLP-1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society Read source
Used Here ForGrounding the protein guidance in a 2025 joint nutrition advisory on GLP-1 treatment.
Good ForPractical nutrition context for weight loss on GLP-1 medicines.
Not ForPredicting whether a specific person will experience hair loss or its severity.
Obesity (Silver Spring) 33(8):1475-1503 - Official Label
FDA-approved prescribing information (Wegovy)
U.S. Food and Drug Administration / Novo NordiskWEGOVY (semaglutide) prescribing information: 6 Adverse Reactions Read source
Used Here ForChecking the hair-loss rate the approved label reports for semaglutide versus placebo.
Good ForThe FDA-approved adverse-reaction rates from the weight-management trials.
Not ForPredicting whether a specific person will lose hair.
FDA-approved labeling, DailyMed (National Library of Medicine), updated June 18, 2026 - Review
Dermatologic Clinics
ElsevierHair loss in systemic disease Read source
Used Here ForExplaining telogen effluvium, the temporary hair shedding that can follow physical stress on the body.
Good ForThe classic clinical description of hair shedding in systemic illness.
Not ForCurrent treatment guidance for hair loss.
Dermatologic Clinics 5(3):565-570